Physician profile
Aly Hashim
NPI 1700366887
$2,115.79
in general payments reported to CMS, 2019-2025
29 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $44.45 · 2021: $210 · 2022: $573 · 2023: $707 · 2024: $153 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.33 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $276.49 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $258.42 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $231.45 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $154.30 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $149.02 | 2022-2023 | |
| Glaxosmithkline, LLC. | $135.07 | 2021-2023 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $117.43 | 2022 | |
| Astellas Pharma US INC | $110.21 | 2023 | |
| Pfizer INC. | $101.31 | 2025 | |
| Janssen Pharmaceuticals, INC | $74.20 | 2023-2024 | Spravato |
| Amgen INC. | $48.64 | 2022 | |
| Merck Sharp & Dohme LLC | $48.19 | 2021-2023 | Gardasil 9, Vaxneuvance, Proquad |
| Biohaven Pharmaceutical Holding Company LTD. | $45.71 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.60 | 2021 | |
| Phadia US INC. | $36.00 | 2020-2023 | Immunocap |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.86 | 2021 | |
| Axsome Therapeutics, INC. | $28.42 | 2025 | Auvelity |
| Genentech, INC. | $27.40 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $26.30 | 2023 | Evkeeza |
| Allergan, INC. | $24.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.30 | 2022 | |
| Genentech USA, INC. | $19.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.91 | 2022 | |
| Surgenex LLC | $17.37 | 2025 | Ardeograft, Pellograft, Surmatrix |
| Dynavax Technologies Corporation | $16.64 | 2023 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $14.92 | 2021 | |
| Currax Pharmaceuticals LLC | $13.00 | 2023 | Contrave |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2021 | |
| Cequr Corporation | $12.47 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aly Hashim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.